Compare ARVN & ERII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | ERII |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 595.9M |
| IPO Year | 2018 | 2008 |
| Metric | ARVN | ERII |
|---|---|---|
| Price | $10.04 | $9.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 3 |
| Target Price | $15.05 | ★ $17.07 |
| AVG Volume (30 Days) | 640.4K | ★ 721.9K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | 5.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | $134,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.55 |
| P/E Ratio | ★ N/A | $27.71 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.90 | $9.35 |
| 52 Week High | $14.22 | $18.31 |
| Indicator | ARVN | ERII |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 35.36 |
| Support Level | $9.96 | N/A |
| Resistance Level | $10.18 | $11.54 |
| Average True Range (ATR) | 0.55 | 0.49 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 20.36 | 6.61 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.